跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
MVASI - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
MVASI
Authorized
STANDARD
MVASI
Amgen Canada Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
2a87ee3fa53e100d
Company
Amgen Canada Inc
Type
Standard
Approval Details
Approval Id
2a87ee3fa53e100d
Drug Approval Canada Name
MVASI
Product Name
MVASI
Status
Marketed
Status Date
2019-08-01
Original Market Date
2019-08-01
Din
02470748
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
Schedule D , Prescription
Ahfs
10:00.00
Atc Original
L01FG01 BEVACIZUMAB
Atc Name
l 01 fg 01
Aig Number
0151381001
Company Name
Amgen Canada Inc
Company Address
300, 6775 Financial Drive, Mississauga, Ontario, Canada, L5N 0A4
Active Ingredients
BEVACIZUMAB
25 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
2a87ee3fa53e100d
Type
Standard
Back to Health Canada Approvals